Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Patrick A. Ott, Sarina A. Piha‐Paul et al.|Journal of Thoracic Oncology|2019Cited by 437
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma studyLeila Khoja, Anthony M. Joshua, Peter Huppert et al.|Annals of Oncology|2019Cited by 282
Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín et al.|Journal of Clinical Oncology|2018Cited by 208
Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II studyF. Mouriaux, Florence Joly, Vincent Servois et al.|British Journal of Cancer|2016Cited by 48
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patientsMathilde Saint‐Ghislain, Manuel Rodrigues, Anne‐Céline Derrien et al.|European Journal of Cancer|2022Cited by 37